ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1228

Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials
Abstract Number: 1135

Barriers to Influenza Vaccination in Patients at a Tertiary Care Rheumatology Clinic
Abstract Number: 1832

Barriers to Medication Adherence and Degree of Nonadherence in a Systemic Lupus Erythematosus Outpatient Population
Abstract Number: 0587

Barriers to Rheumatologic Care and Antimalarial Refills Among a Cohort of Patients with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Abstract Number: 1362

BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study
Abstract Number: 0390

Baseline Characteristics of Systemic Sclerosis (SSc) Patients with Restrictive Lung Disease in a Multi-Center United States Based Longitudinal Registry
Abstract Number: 0698

Baseline Factors Are Not Associated with Rehabilitation Dose over Six Months Among Adults with RA
Abstract Number: 2016

Baseline Serum Biomarker Levels Predict Spinal Radiographic Progression in Ankylosing Spondylitis Patients on TNF Inhibitor Therapy
Abstract Number: 1762

Benefit and Risk Profiles of Janus Kinase Inhibitors Approved in the US for the Treatment of RA
Abstract Number: 1487

Biclustering Reveals Potential Knee Osteoarthritis Phenotypes in Exploratory Analyses: Data from the Osteoarthritis Initiative
Abstract Number: 0986

BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
Abstract Number: 1653

Bilateral vs Unilateral Total Knee Arthroplasty: Racial Variation in Utilization and In-Hospital Major Complication Rates
Abstract Number: 0356

Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
Abstract Number: 1364

Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study
Abstract Number: 1352

Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].